HealthRX.com · Printable symptom log
Long COVID symptom and exertion record to review before any MOTS-c decision
Captures the baseline, daily effort and next-day symptoms that this page's checkpoint table relies on, so a clinician can judge any change against a record rather than memory, with the evidence facts a MOTS-c conversation needs.
Starting point
Date of COVID-19 infection or positive test
Main symptoms now, in your own words
Other causes already checkedthyroid, anemia, sleep, mood, medicines
Current medicines and supplements
Any MOTS-c-labelled product being considered, and where it would come from
Daily effort and next-day symptoms
Symptoms that flare a day or two after effort are worth recording on the later date too.
| Date | Activity and how hard it felt | Symptoms that day | Symptoms the next day | Sleep |
|---|---|---|---|---|
Evidence to bring to the conversation
- The trial number this page cites, NCT05683366, is registered as a pulse-oximetry device study, not a MOTS-c trial.[1]
- FDA's July 2026 review identified no clinical studies or human exposure data for MOTS-c by any route.[2]
- One study found lower MOTS-c in blood vesicles of long COVID patients with neuropsychiatric symptoms; it measured the body's own peptide.[3]
- Another found higher serum MOTS-c during acute COVID-19, so the reported direction has differed by sample type and stage of illness.[4]
For your clinician or long COVID clinic
- Which other causes of my symptoms still need to be ruled out?
- What would count as real improvement for me, and how will we measure it first?
- How should I pace activity so that effort does not make the next days worse?
- With no MOTS-c study in long COVID, what treatments with evidence should we try first?
- Is there a long COVID research study I could ask to join?
Sources for the facts on this sheet
- U.S. National Library of Medicine, ClinicalTrials.gov (API v2 record). NCT05683366: Philps FAST2022 picoSAT Pulse Oximetry Desaturation Study. Accessed 2026-10-19. https://clinicaltrials.gov/api/v2/studies/NCT05683366
- U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. Accessed 2026-10-19. https://www.fda.gov/media/193347/download
- Goetzl EJ, Yao PJ, Kapogiannis D. Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19. Am J Med 2023. PMID 37072092. https://pubmed.ncbi.nlm.nih.gov/37072092/
- Saracaloglu A, Mete AÖ, Ucar DF, Demiryürek S, Erbagcı E, Demiryürek AT. Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects. Curr Protein Pept Sci 2023. PMID 36799414. https://pubmed.ncbi.nlm.nih.gov/36799414/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.